Date: 2014-10-30
Type of information: Licensing agreement
Compound: Interactive Protein Screening and Reengineering Interface (ISPRI)
Company: Chugai Pharmaceutical (Japan) Epivax (USA - RI)
Therapeutic area: Technology - Services
Type agreement: licensing
Action mechanism: Interactive Protein Screening and Reengineering Interface (ISPRI) is an interactive biologics screening and optimizing work environment that can be used for high throughput unlimited screening of partial and complete sequences of biological (protein therapeutic) candidates. The toolkit can be used to identify within each protein sequence potentially immunogenic regions (known as epitope clusters) and to fine map those individual amino acids which contribute most to the immunogenic potential of the cluster. The output is customized to best fit the needs and preferences of your biologics team.
Disease:
Details: * On October 30, 2014, Chugai Pharmaceutical signed an agreement with Rhode Island-based biotechnology company, EpiVax, , to incorporate EpiVax\'s ISPRI immunogenicity screening and deimmunization technology into Chugai\'s drug development toolbox. Researchers at Chugai will be utilizing the cloud-based in silico \"Interactive Protein Screening and Reengineering Interface\" (ISPRI) in conjunction with OptiMatrix, a tool for deimmunizing biologics, to screen and re-engineer therapeutic proteins for potential immunogenicity and deimmunize immune-dominant epitopes, known as clusters.
Financial terms:
Latest news:
